PHAXIAM Therapeutics (PHXM) 6-K Current report (foreign)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2020

Commission File Number:001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:

☒  Form20-F            ☐  Form40-F

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7):  ☐

INFORMATION CONTAINED IN THIS REPORT ONFORM 6-K

Press Release

On June 25, 2020, Erytech Pharma S.A. (the “Company”) issued a press release regarding a convertible bond financing. A copy of the press release is attached to this Report on Form6-K as Exhibit 99.1.

EXHIBITS

Exhibit	Description
99.1	Press Release dated June 25, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ERYTECH Pharma S.A.
Date: June 25, 2020	By:	/s/ Eric Soyer
		Name	Eric Soyer
		Title:	Chief Financial Officer and Chief Operating Officer